|
Progesterone Resistance
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Female infertility
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Sixty-five percent (53/82) of ovarian adenocarcinomas, 57% (8/14) of benign/borderline tumours and only 31% (5/16) of normal ovarian tissues studied showed specific 125I-EGF (epidermal growth factor) binding (median: 17; 10; and 0 fmol EGF-R/mg protein, respectively) and a significant increase in progesterone receptor (PgR) levels was observed in these groups (median: 5; 33; and 152 fmol/mg protein, respectively).
|
1325950 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All c-myc-amplified tumours were PgR-negative.
|
1325950 |
1992 |
|
Invasive Ductal Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong positive staining for p185 protein was found in 10 patients (20%) with infiltrating ductal breast carcinoma and correlated with complete negative estrogen/progesterone receptor status and with histologic grade G3.
|
1347986 |
1992 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2/neu amplification was negatively correlated with oestrogen receptor (ER) and progesterone receptor (PR) status (P less than 0.0001; for both), c-myc amplification was more prevalent in the PR-negative subpopulation (P less than 0.05) and int-2/bcl-1 amplification was positively correlated with ER status (P less than 0.001).
|
1350457 |
1992 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genetic evolution of breast cancer: II. Relationship with estrogen and progesterone receptor expression.
|
1391976 |
1992 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genetic evolution of breast cancer: II. Relationship with estrogen and progesterone receptor expression.
|
1391976 |
1992 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
No staining was seen in benign samples, whereas intense nuclear staining of cancer cells consistent with overexpression of the p53 protein was observed in 22 of 107 cancers (21%). p53 overexpression was more frequent in advanced (Stage III/IV) cancers (41%) than in early (Stage I/II) cancers (9%) (P less than 0.001), and also was associated with nonendometrioid histology (P = 0.008), positive peritoneal cytology (P = 0.01), extrauterine metastases (P = 0.003), and negative progesterone receptor status (P = 0.04).
|
1540970 |
1992 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
No staining was seen in benign samples, whereas intense nuclear staining of cancer cells consistent with overexpression of the p53 protein was observed in 22 of 107 cancers (21%). p53 overexpression was more frequent in advanced (Stage III/IV) cancers (41%) than in early (Stage I/II) cancers (9%) (P less than 0.001), and also was associated with nonendometrioid histology (P = 0.008), positive peritoneal cytology (P = 0.01), extrauterine metastases (P = 0.003), and negative progesterone receptor status (P = 0.04).
|
1540970 |
1992 |
|
Human papilloma virus infection
|
0.030 |
Biomarker
|
disease |
BEFREE |
According to recent studies showing that human papillomavirus (HPV) infections can be influenced by sex steroid hormones, we performed estrogen (ER) and progesterone (PgR) receptor assays in fresh frozen biopsies of genital-HPV-related lesions.
|
1646176 |
1991 |
|
Cervical Intraepithelial Neoplasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between the sex steroid receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and the cell proliferation kinetics during the menstrual cycle in normal and neoplastic epithelium of the uterine cervix, immunohistochemical localization of ER, PR, and cell proliferation-associated antigen, Ki-67, was investigated in 35 normal cervical specimens, 3 condylomas, 26 cervical intraepithelial neoplasia (CIN) samples, and 22 invasive squamous carcinoma samples.
|
1651807 |
1991 |
|
Condyloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between the sex steroid receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and the cell proliferation kinetics during the menstrual cycle in normal and neoplastic epithelium of the uterine cervix, immunohistochemical localization of ER, PR, and cell proliferation-associated antigen, Ki-67, was investigated in 35 normal cervical specimens, 3 condylomas, 26 cervical intraepithelial neoplasia (CIN) samples, and 22 invasive squamous carcinoma samples.
|
1651807 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic value of p185/p21 co-expression was particularly significant in progesterone-receptor-positive tumors.
|
1672666 |
1991 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Neither the HindIII RFLP nor the deletion defined by Pst I and Sst I correlated with PgR expression as determined by a ligand-binding assay, suggesting that neither is related to the heterogeneity of PgR expression seen in breast tumors.
|
1679459 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have examined the ability of estradiol (E2) to regulate the expression of three mRNAs [for pS2, progesterone receptor (PR), and estrogen receptor (ER)], known to be under E2 regulation in the parental E2 growth-responsive MCF-7 cells, in an E2 growth-independent MCF-7 K3), previously isolated from the parental estrogen-dependent MCF-7 K1 human breast cancer cells after long term growth in vitro in the absence of estrogen, acquired estrogen-independent growth in vitro as well as the ability to form tumors in nude mice in vivo without estrogen.
|
1722871 |
1991 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is fairly well accepted that the presence of estrogen receptor (ER) and progesterone receptor (PgR) identifies breast cancer patients with a lower risk of relapse and better overall survival.
|
1728420 |
1992 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is fairly well accepted that the presence of estrogen receptor (ER) and progesterone receptor (PgR) identifies breast cancer patients with a lower risk of relapse and better overall survival.
|
1728420 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In group I more patients with histopathological tumor grade III and negative estrogen (ER) and progesterone receptor (PR) levels were found, but the metastatic involvement of regional lymph nodes was similar in both groups.
|
1728611 |
1992 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated the estrogen-like effects of tamoxifen on the acceleration of growth and increased progesterone receptor concentrations of human endometrial carcinomas grown in the nude mouse experimental model.
|
1733196 |
1992 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latter included: tumour grade, oestrogen and progesterone receptor status, thymidine labelling index, DNA ploidy, S-phase fraction, epidermal growth factor receptor expression and c-erbB-2 gene amplification (or overexpression).
|
1838260 |
1991 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a non-parametric test (Kruskal-Wallis) a strong negative association was found between high levels of c-erbB2 amplification and absence of estrogen receptor (ER) (P = .0009) or progesterone receptor (PR) (P = .011) expression.
|
1980125 |
1990 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since progesterone receptor (PgR) is normally induced by estrogen, breast cancer lacking estrogen receptor (ER) would also be expected to lack PgR.
|
1988075 |
1991 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since progesterone receptor (PgR) is normally induced by estrogen, breast cancer lacking estrogen receptor (ER) would also be expected to lack PgR.
|
1988075 |
1991 |